AR084698A1 - Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentos - Google Patents
Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentosInfo
- Publication number
- AR084698A1 AR084698A1 ARP110102144A ARP110102144A AR084698A1 AR 084698 A1 AR084698 A1 AR 084698A1 AR P110102144 A ARP110102144 A AR P110102144A AR P110102144 A ARP110102144 A AR P110102144A AR 084698 A1 AR084698 A1 AR 084698A1
- Authority
- AR
- Argentina
- Prior art keywords
- controlled release
- inhibitors
- active agent
- composition
- pharmaceutical
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 6
- 230000009246 food effect Effects 0.000 title abstract 4
- 235000021471 food effect Nutrition 0.000 title abstract 4
- 230000003993 interaction Effects 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 239000000556 agonist Substances 0.000 abstract 3
- 230000002058 anti-hyperglycaemic effect Effects 0.000 abstract 3
- 108010073466 Bombesin Receptors Proteins 0.000 abstract 2
- 102100030671 Gastrin-releasing peptide receptor Human genes 0.000 abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940127322 Sodium-Glucose Transporter 2 Inhibitors Drugs 0.000 abstract 2
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 abstract 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 2
- 229960003105 metformin Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- -1 rosigllone Chemical compound 0.000 abstract 2
- 150000001467 thiazolidinediones Chemical class 0.000 abstract 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 abstract 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 abstract 1
- 229940123208 Biguanide Drugs 0.000 abstract 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 abstract 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 abstract 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 abstract 1
- 108010011459 Exenatide Proteins 0.000 abstract 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 abstract 1
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 abstract 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 abstract 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 abstract 1
- 101710163236 Glucose-dependent insulinotropic receptor Proteins 0.000 abstract 1
- 102000004366 Glucosidases Human genes 0.000 abstract 1
- 108010056771 Glucosidases Proteins 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 abstract 1
- 108010019598 Liraglutide Proteins 0.000 abstract 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 abstract 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 229940100389 Sulfonylurea Drugs 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 229960002632 acarbose Drugs 0.000 abstract 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract 1
- 229960004733 albiglutide Drugs 0.000 abstract 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 abstract 1
- 229960001667 alogliptin Drugs 0.000 abstract 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 150000004283 biguanides Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229960001761 chlorpropamide Drugs 0.000 abstract 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 abstract 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 229950003693 dutogliptin Drugs 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- 229960000346 gliclazide Drugs 0.000 abstract 1
- 229960004346 glimepiride Drugs 0.000 abstract 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 abstract 1
- 229960001381 glipizide Drugs 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 229960002397 linagliptin Drugs 0.000 abstract 1
- 229960002701 liraglutide Drugs 0.000 abstract 1
- 229950004994 meglitinide Drugs 0.000 abstract 1
- 229960001110 miglitol Drugs 0.000 abstract 1
- 229960000698 nateglinide Drugs 0.000 abstract 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 abstract 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
- 108700027806 rGLP-1 Proteins 0.000 abstract 1
- 229960002354 repaglinide Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960004937 saxagliptin Drugs 0.000 abstract 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 abstract 1
- 108010033693 saxagliptin Proteins 0.000 abstract 1
- 229960004034 sitagliptin Drugs 0.000 abstract 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1
- 229960001641 troglitazone Drugs 0.000 abstract 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 abstract 1
- 229960001254 vildagliptin Drugs 0.000 abstract 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica de liberación controlada que exhibe un reducido efecto de alimentos.Reivindicación 1: Una composición farmacéutica de liberación controlada con reducido efecto de alimentos, en donde dicha composición comprende un agente activo y al menos un excipiente farmacéuticamente aceptable, en donde dicho agente activo tiene una ventana de absorción limitada y muestra un efecto de alimentos negativo cuando se administra una forma de dosificación de liberación inmediata de dicho agente activo por vía oral a un sujeto. Reivindicación 9: La composición farmacéutica de liberación controlada de la reivindicación 1, en donde dicho agente activo es metformina una sal farmacéuticamente aceptable de ella. Reivindicación 11: La composición farmacéutica de liberación controlada de la reivindicación 10, en donde dichos fármacos antihiperglucémicos actualmente disponibles incluyen, aunque no a modo de limitación, sulfonilurea, biguanidas, inhibidores de glucosidasa a, tiazolidindionas (TZD), inhibidores de dipeptidil peptidasa-4 (inhibidores de DPP-4), meglitinidas, análogos del péptido 1 tipo glucagón (análogos de GLP-1) e insulina. Reivindicación 12: La composición farmacéutica de liberación controlada de la reivindicación 10, en donde los fármacos antihiperglucémicos incluyen, aunque no a modo de limitación, metformina, gliburida, glimepirida glipirida, glipizida, clorpropamida, gliclazida, acarbosa, miglitol, pioglitazona, troglitazona, rosiglitazona, isaglitazona, muraglitizar, peliglitazar, sitagliptina, saxagliptina, vildagliptina, alogliptina, linagliptina, dutogliptina, repaglinida, nateglinida, mitiglindina, exenatida, liraglutida, albiglutida e insulina. Reivindicación 13: La composición farmacéutica de liberación controlada de la reivindicación 10, en donde dichos fármacos antihiperglucémicos experimentales incluyen, aunque no a modo de limitación, moduladores de IL-1, inhibidores del transportador 2 de sodio-glucosa (SGLT- 2), moduladores duales de PPAR, inhibidores de deshidrogenasa 11b-hidroxiesteroide (HSD), antagonistas de CCR2, inhibidores selectivos de fructosa 1,6-bisfosfatasa, moduladores inmunológicos, inhibidores de la síntesis de cortisol, agonistas del receptor del péptido liberador de gastrina (GRP), agonistas del receptor 119 acoplado a la proteína G (GPR 119), agonistas del receptor 4 tipo Toll (TLR-4), antagonistas de FXR y fármacos antisentido que apuntan a los receptores de glucagón.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35725110P | 2010-06-22 | 2010-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084698A1 true AR084698A1 (es) | 2013-06-05 |
Family
ID=45328888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102144A AR084698A1 (es) | 2010-06-22 | 2011-06-21 | Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8486453B2 (es) |
| EP (1) | EP2585052A4 (es) |
| JP (1) | JP2013533241A (es) |
| KR (1) | KR20140007247A (es) |
| CN (1) | CN103037849A (es) |
| AR (1) | AR084698A1 (es) |
| AU (1) | AU2011271124A1 (es) |
| BR (1) | BR112012032816A2 (es) |
| CA (1) | CA2802335A1 (es) |
| MX (1) | MX2012015188A (es) |
| RU (1) | RU2012155890A (es) |
| TW (1) | TW201206503A (es) |
| WO (1) | WO2011163206A2 (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| HUE050287T2 (hu) | 2009-02-13 | 2020-11-30 | Boehringer Ingelheim Int | SGLT2-inhibitort, DPP-IV-inhibitort és adott esetben egy további antidiabetikus hatóanyagot tartalmazó gyógyászati készítmény és alkalmazásai |
| EP2504002B1 (en) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| KR20200028498A (ko) | 2010-06-24 | 2020-03-16 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US20130251795A1 (en) * | 2010-07-30 | 2013-09-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| HUE061596T2 (hu) | 2011-07-15 | 2023-07-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben |
| BR112014020186A8 (pt) * | 2012-02-22 | 2017-07-11 | Duchesnay Inc | Formulação de doxilamina e piridoxina e/ou seus metabólitos ou sais |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| ES2929025T3 (es) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| UY34856A (es) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
| WO2014080383A1 (en) * | 2012-11-26 | 2014-05-30 | Ranbaxy Laboratories Limited | Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics |
| EP3024466B1 (en) | 2013-07-22 | 2018-04-04 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
| US9452181B2 (en) | 2013-07-22 | 2016-09-27 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
| CN103655570B (zh) * | 2013-12-11 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 西格列汀与二甲双胍复方缓释制剂及其制备方法 |
| CN104739835A (zh) * | 2013-12-30 | 2015-07-01 | 中美华世通生物医药科技（武汉）有限公司 | 一种治疗糖尿病的新型药物组合物 |
| US9902751B2 (en) | 2013-12-30 | 2018-02-27 | Mylan Laboratories Limited | Process for the preparation of empagliflozin |
| KR101633292B1 (ko) * | 2014-02-25 | 2016-06-24 | 동아에스티 주식회사 | 용법이 개선된 엔테카비어를 함유하는 약학적 조성물 |
| WO2015130083A1 (ko) * | 2014-02-25 | 2015-09-03 | 동아에스티 주식회사 | 용법이 개선된 엔테카비어를 함유하는 약학적 조성물 |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| CA2949236C (en) | 2014-05-15 | 2023-06-13 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CN105287581A (zh) * | 2014-07-15 | 2016-02-03 | 上海星泰医药科技有限公司 | 阿格列汀二甲双胍缓释片及其制备方法 |
| US9526703B2 (en) | 2014-08-29 | 2016-12-27 | Duchesnay Inc. | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
| RU2690372C2 (ru) * | 2015-04-20 | 2019-06-03 | Тви Биотекнолоджи, Инк. | Лекарственные средства, содержащие диацереин, и способы снижения уровней мочевой кислоты в крови с его использованием |
| TWI684465B (zh) * | 2015-04-22 | 2020-02-11 | 安成生物科技股份有限公司 | 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法 |
| CN105055413A (zh) * | 2015-07-23 | 2015-11-18 | 上海市第六人民医院 | 一种小檗碱和瑞格列奈的药物组合物 |
| CN105496970A (zh) * | 2015-12-18 | 2016-04-20 | 北京华禧联合科技发展有限公司 | 含有利格列汀的组合物及其制备方法 |
| CN106924208A (zh) * | 2015-12-30 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种复方达格列净二甲双胍缓释片及其制备方法 |
| WO2017153939A1 (en) * | 2016-03-10 | 2017-09-14 | Aurobindo Pharma Limited | Pharmaceutical composition comprising canagliflozin, process of preparation and use thereof |
| BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
| US11191802B2 (en) | 2018-04-06 | 2021-12-07 | AMMA Therapeutics, Inc. | Composition for controlled release of therapeutic agents |
| IT201800011119A1 (it) | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide per la somministrazione cronotropica di sitagliptin |
| TR201916829A2 (tr) * | 2019-10-31 | 2021-05-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari |
| CN110974792A (zh) * | 2019-12-26 | 2020-04-10 | 南京亿华药业有限公司 | 一种结晶性药物片剂及其制备方法 |
| WO2022073151A1 (en) * | 2020-10-05 | 2022-04-14 | Theracos Sub, Llc | Pharmaceutical formulations |
| KR20250154775A (ko) * | 2024-04-22 | 2025-10-29 | 제이피바이오 주식회사 | 다파글리플로진, 리나글립틴 및 메트포르민을 포함하는 안정성이 향상된 약제학적 제제 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| US6360257B1 (en) * | 1998-01-30 | 2002-03-19 | Telefonaktiebolaget L M Ericsson (Publ) | Managing group IP addresses in mobile end stations |
| US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
| CA2494281A1 (en) * | 2002-08-02 | 2004-02-12 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
| AU2003272504A1 (en) * | 2002-09-20 | 2004-04-08 | Andrx Labs Llc | Multistage formulation containing a biguanide and thiazolidindione derivatives |
| US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| CA2536111A1 (en) * | 2003-07-24 | 2005-02-03 | Wockhardt Limited | Oral compositions for treatment of diseases |
| CN1901880A (zh) * | 2003-10-31 | 2007-01-24 | 阿尔扎公司 | 用于增加二甲双胍吸收的组合物和剂型 |
| JP2007509973A (ja) * | 2003-10-31 | 2007-04-19 | アルザ・コーポレーシヨン | 増強された吸収のための組成物および投与形態物 |
| WO2010045656A2 (en) * | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
-
2011
- 2011-06-21 JP JP2013516682A patent/JP2013533241A/ja active Pending
- 2011-06-21 BR BR112012032816A patent/BR112012032816A2/pt not_active IP Right Cessation
- 2011-06-21 WO PCT/US2011/041218 patent/WO2011163206A2/en not_active Ceased
- 2011-06-21 AU AU2011271124A patent/AU2011271124A1/en not_active Abandoned
- 2011-06-21 RU RU2012155890/15A patent/RU2012155890A/ru not_active Application Discontinuation
- 2011-06-21 EP EP11798742.0A patent/EP2585052A4/en not_active Withdrawn
- 2011-06-21 CA CA2802335A patent/CA2802335A1/en not_active Abandoned
- 2011-06-21 AR ARP110102144A patent/AR084698A1/es unknown
- 2011-06-21 US US13/164,995 patent/US8486453B2/en not_active Expired - Fee Related
- 2011-06-21 MX MX2012015188A patent/MX2012015188A/es active IP Right Grant
- 2011-06-21 CN CN201180031366XA patent/CN103037849A/zh active Pending
- 2011-06-21 KR KR1020127033481A patent/KR20140007247A/ko not_active Withdrawn
- 2011-06-22 TW TW100121863A patent/TW201206503A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2802335A1 (en) | 2011-12-29 |
| WO2011163206A3 (en) | 2012-03-01 |
| JP2013533241A (ja) | 2013-08-22 |
| BR112012032816A2 (pt) | 2016-11-08 |
| EP2585052A2 (en) | 2013-05-01 |
| CN103037849A (zh) | 2013-04-10 |
| US8486453B2 (en) | 2013-07-16 |
| TW201206503A (en) | 2012-02-16 |
| RU2012155890A (ru) | 2014-07-27 |
| EP2585052A4 (en) | 2014-10-01 |
| WO2011163206A4 (en) | 2012-04-26 |
| WO2011163206A2 (en) | 2011-12-29 |
| US20110311594A1 (en) | 2011-12-22 |
| MX2012015188A (es) | 2013-05-20 |
| KR20140007247A (ko) | 2014-01-17 |
| AU2011271124A1 (en) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084698A1 (es) | Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentos | |
| JP2013533241A5 (es) | ||
| US20060160736A1 (en) | Pharmaceutical compositions and methods for restoring beta-cell mass and function | |
| Cefalo et al. | Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives | |
| JP2013199505A5 (es) | ||
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| HRP20170478T1 (hr) | Farmaceutski pripravci albiglutida | |
| JP2017515908A5 (es) | ||
| ES2900843T3 (es) | Método para suprimir la secreción de glucagón de un inhibidor de sglt2 | |
| CA2724133C (en) | Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine | |
| AR082767A1 (es) | Terapia para la diabetes | |
| AR079939A1 (es) | Composicion farmaceutica para tratar un sindrome metabolico | |
| AR077464A1 (es) | Terapia de combinacion para el tratamiento de la diabetes | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| JP2018507889A5 (es) | ||
| Seetharaman et al. | One hundred years since insulin discovery: an update on current and future perspectives for pharmacotherapy of diabetes mellitus | |
| JP2024515137A (ja) | Ｇｐｒ４０アゴニスト及びｓｇｌｔ－２阻害剤を含む医薬組成物 | |
| RU2012147449A (ru) | Способы использования диацереина в дополнительном лечении диабета | |
| JP2020518556A5 (es) | ||
| ES2610362T3 (es) | Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1 | |
| US20130122050A1 (en) | Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide | |
| AR104503A2 (es) | Compuestos heterocíclicos de ácido borónico | |
| WO2007146786A1 (en) | Pharmaceutical compositions and methods for restoring b-cell mass and function | |
| Irwin et al. | Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes | |
| LU | Therapeutic effect of Acarbose in combination with other hypoglycemic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |